Johnson & Johnson on Tuesday reported quarterly earnings and revenue that topped Wall Street’s expectations, and lifted its full-year guidance as sales in the company’s pharmaceutical and medical devices businesses surged.It marks J&J’s first quarterly results since it completed the separation from its consumer health spinoff Kenvue in August, the company’s biggest shake-up in its 137-year history.Upon that separation in August, J&J also lowered its full-year sales and profit guidance.The drugmaker raised that revised outlook on Tuesday: J&J expects 2023 sales of $83.6 billion to $84 billion,compared with previous guidance of $83.2 billion to $84 billion in August.

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4% and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%.
Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%
Company is increasing 2023 full-year guidance midpoints for sales5 and adjusted EPS

Overall Financial Results

Q3

($ in millions, except EPS)        2023         2022      % Change
Reported Sales                      $21,351    $19,996      6.8%
Net Earnings                         $4,309      $4,310       0.0%
EPS (diluted)                        $1.69        $1.62         4.3%

Q3

Non-GAAP* ($ in Millions, except EPS)     2023     2022     % Change

Operational Sales                                                            6.4%
Adjusted Operational Sales                                              4.9%
Adjusted Net Earnings                        $6,777    $5,938    14.1%
Adjusted EPS (diluted)                       $2.66      $2.23      19.3%

Regional Sales Results

Q3 % Change
($ in Millions)      2023        2022        Reported    Operational    Currency    Adjusted Operational
U.S.                 $11,996    $10,794       11.1%         11.1               –                       8.9
International    $9,355      $9,202         1.6%           0.7               0.9                     0.3
Worldwide       $21,351     $19,996       6.8%           6.4               0.4                     4.9

Segment Sales Results

Q3 % Change
($ in Millions)                2023       2022        Reported    Operational  Currency  Adjusted Operational
Innovative Medicine       $13,893   $13,214      5.1%           4.3          0.8                  4.4
MedTech                      $7,458     $6,782       10.0%         10.4          0.4                  6.0
Worldwide                    $21,351   $19,996      6.8%          6.4           0.4                  4.9

About CareFix

CareFix is a professional national high-tech enterprise engaged in orthopedic medical equipment design, production, sales and service. Founded in 2009, we’ve devoted to  pediatric implants,foot & ankle implant,external fixation and spinal implants. Welcome to visit to our factory,it’s about half an hour from Shanghai Hongqiao Airport.